{"hands_on_practices": [{"introduction": "The effectiveness of a sunscreen is not a fixed property but depends critically on how it is applied. This exercise demonstrates the profound difference between the labeled Sun Protection Factor ($SPF$), measured under ideal lab conditions, and the actual protection achieved in the real world where application is often less generous. By applying the Beer-Lambert law, you will derive a quantitative relationship between application density and $SPF$, revealing why user habits are a key determinant of photoprotection. [@problem_id:4936246]", "problem": "A topical sunscreen is labeled with a Sun Protection Factor (SPF) measured under standard testing conditions at an application density of $2$ mg/cm$^{2}$. In photoprotection pharmacology, a common physical starting point is that the erythemally effective ultraviolet irradiance transmitted through an absorbing film follows the Beer–Lambert law, which in its standard form states that the transmitted fraction $T$ through a uniform absorbing layer of thickness $\\ell$ and concentration $c$ is $T=\\exp(-\\epsilon c \\ell)$, where $\\epsilon$ is a constant attenuation coefficient. For a sunscreen film of uniform density on skin, the mass per unit area $m$ is related to the film thickness $\\ell$ by $m=\\rho \\ell$, where $\\rho$ is the film density, and the erythema-weighted attenuation per unit mass can be treated as a constant over the relevant band. The Sun Protection Factor (SPF) is defined operationally as the ratio of the minimal erythema dose without sunscreen to that with sunscreen, and in the monochromatic, erythema-weighted approximation can be treated as the reciprocal of the transmitted fraction, $\\mathrm{SPF}=1/T$.\n\nAssume a sunscreen product has a labeled $\\mathrm{SPF}_{\\mathrm{label}}=50$ at the reference application density $m_{\\mathrm{ref}}=2$ mg/cm$^{2}$. Using only the principles stated above, derive from first principles a general expression for $\\mathrm{SPF}(m)$ as a function of $m$ and $\\mathrm{SPF}_{\\mathrm{label}}$ and use it to compute the transmitted fraction $T(m)$ and the blocked fraction $1-T(m)$ at application densities $m \\in \\{0.5, 1.0, 1.5, 2.0\\}$ mg/cm$^{2}$. Finally, use your derived expression to predict the real-world $\\mathrm{SPF}$ when only $m=1.0$ mg/cm$^{2}$ is applied.\n\nFor reporting, provide only the predicted $\\mathrm{SPF}$ at $m=1.0$ mg/cm$^{2}$ as a unitless number rounded to three significant figures.", "solution": "We begin from the Beer–Lambert law, which states that the transmitted fraction of irradiance through an absorbing layer is $T=\\exp(-\\epsilon c \\ell)$, where $\\epsilon$ is an attenuation coefficient, $c$ is the concentration, and $\\ell$ is the path length. For a uniform sunscreen film on skin, it is convenient to express attenuation per unit mass per area. Let the film have density $\\rho$ and thickness $\\ell$, so that the mass per unit area is $m=\\rho \\ell$. If the erythema-weighted effective attenuation per unit mass is constant and equal to $k$ (with units of area per mass), then the transmitted fraction as a function of application density $m$ can be written as\n$$\nT(m)=\\exp(-k m).\n$$\nThe Sun Protection Factor (SPF) is operationally defined as the ratio of minimal erythema dose without sunscreen to that with sunscreen. Under a monochromatic, erythema-weighted approximation, this is equivalent to\n$$\n\\mathrm{SPF}(m)=\\frac{1}{T(m)}.\n$$\nAt the reference application density $m_{\\mathrm{ref}}=2$ mg/cm$^{2}$, the labeled SPF is $\\mathrm{SPF}_{\\mathrm{label}}$, hence\n$$\n\\mathrm{SPF}_{\\mathrm{label}}=\\frac{1}{T(m_{\\mathrm{ref}})}=\\frac{1}{\\exp(-k m_{\\mathrm{ref}})}=\\exp(k m_{\\mathrm{ref}}).\n$$\nTaking the natural logarithm of both sides yields\n$$\n\\ln\\!\\big(\\mathrm{SPF}_{\\mathrm{label}}\\big)=k\\, m_{\\mathrm{ref}},\n$$\nso\n$$\nk=\\frac{\\ln\\!\\big(\\mathrm{SPF}_{\\mathrm{label}}\\big)}{m_{\\mathrm{ref}}}.\n$$\nSubstituting this back into $T(m)$ gives\n$$\nT(m)=\\exp\\!\\left(-\\frac{\\ln\\!\\big(\\mathrm{SPF}_{\\mathrm{label}}\\big)}{m_{\\mathrm{ref}}}\\, m\\right)=\\exp\\!\\left(\\ln\\!\\big(\\mathrm{SPF}_{\\mathrm{label}}^{-m/m_{\\mathrm{ref}}}\\big)\\right)=\\mathrm{SPF}_{\\mathrm{label}}^{-m/m_{\\mathrm{ref}}}.\n$$\nTherefore, the general expression for SPF as a function of $m$ is\n$$\n\\mathrm{SPF}(m)=\\frac{1}{T(m)}=\\mathrm{SPF}_{\\mathrm{label}}^{\\,m/m_{\\mathrm{ref}}}.\n$$\n\nWith $\\mathrm{SPF}_{\\mathrm{label}}=50$ and $m_{\\mathrm{ref}}=2$ mg/cm$^{2}$, the transmitted fraction is\n$$\nT(m)=50^{-m/2}.\n$$\nWe can now compute $T(m)$ and $1-T(m)$ at the specified application densities:\n- For $m=2.0$ mg/cm$^{2}$: $T(2.0)=50^{-1}= \\frac{1}{50} = 0.02$, and $1-T(2.0)=1-0.02=0.98$.\n- For $m=1.5$ mg/cm$^{2}$: $T(1.5)=50^{-0.75} \\approx 0.0532$, and $1-T(1.5)\\approx 1-0.0532=0.9468$.\n- For $m=1.0$ mg/cm$^{2}$: $T(1.0)=50^{-0.5}=\\frac{1}{\\sqrt{50}}\\approx 0.141421$, and $1-T(1.0)\\approx 1-0.141421=0.858579$.\n- For $m=0.5$ mg/cm$^{2}$: $T(0.5)=50^{-0.25}\\approx 0.376060$, and $1-T(0.5)\\approx 1-0.376060=0.623940$.\n\nFinally, the predicted real-world SPF at $m=1.0$ mg/cm$^{2}$ is\n$$\n\\mathrm{SPF}(1.0)=\\mathrm{SPF}_{\\mathrm{label}}^{\\,1.0/2.0}=50^{1/2}=\\sqrt{50}\\approx 7.071067812.\n$$\nRounding to three significant figures as required gives $7.07$. This is unitless, as SPF is a ratio.", "answer": "$$\\boxed{7.07}$$", "id": "4936246"}, {"introduction": "Combining multiple topical agents is a common strategy in dermatology, but it requires a careful understanding of their chemical compatibility. This practice delves into the kinetic principles behind the well-known interaction between benzoyl peroxide and tretinoin, two mainstays of acne therapy. You will model the degradation of tretinoin under different conditions of light and oxidative stress to quantitatively determine the optimal dosing schedule that maximizes drug stability and efficacy. [@problem_id:4936264]", "problem": "A $21$-year-old with inflammatory and comedonal acne is prescribed topical benzoyl peroxide gel and tretinoin cream. The clinician wants to avoid chemical incompatibility that reduces retinoid efficacy when both agents are present on the skin simultaneously. Use the following fundamental bases to reason from first principles:\n\n- First-order degradation of a drug can be modeled by $dC/dt = -k(t)\\,C(t)$, where $C(t)$ is the intact drug concentration and $k(t)$ is a time-dependent pseudo-first-order rate constant reflecting environmental stressors. The solution is $C(t) = C_0 \\exp\\left(-\\int_0^t k(\\tau)\\,d\\tau\\right)$ for initial concentration $C_0$.\n- Benzoyl Peroxide (BPO) decomposes on skin to benzoyloxyl radicals $\\,\\mathrm{PhCO_2\\cdot}\\,$, which decarboxylate to phenyl radicals $\\,\\mathrm{Ph\\cdot}\\,$ and propagate peroxyl radicals in an oxidizing microenvironment. Conjugated polyenes like tretinoin (all-trans retinoic acid) undergo radical addition and oxidative cleavage along the polyene chain, accelerating degradation.\n- Ultraviolet (UV) radiation increases photodegradation of tretinoin via isomerization and photooxidation; darkness reduces this component.\n\nAssume the following well-tested approximations for rate constants under typical use conditions on facial skin:\n\n- In darkness with no BPO radicals present, tretinoin degrades with $k_{\\mathrm{dark}} = 0.02\\ \\mathrm{h}^{-1}$.\n- In daylight with no BPO radicals, $k_{\\mathrm{light}} = 0.10\\ \\mathrm{h}^{-1}$.\n- When BPO-derived radicals are present, they add an oxidative component $k_{\\mathrm{ox}} = 0.20\\ \\mathrm{h}^{-1}$, so $k_{\\mathrm{dark+ox}} = 0.22\\ \\mathrm{h}^{-1}$ at night and $k_{\\mathrm{light+ox}} = 0.30\\ \\mathrm{h}^{-1}$ in daylight.\n- After BPO application, radical generation is sustained for $T_{\\mathrm{rad}} = 3\\ \\mathrm{h}$, after which $k(t)$ reverts to the non-oxidative baseline determined by ambient light.\n- Clinical efficacy requires that a substantial fraction of intact tretinoin survives the initial $2\\ \\mathrm{h}$ post-application window while partitioning into the viable epidermis.\n\nFor each dosing regimen below, compute the fraction $C(2)/C_0$ of intact tretinoin after $2\\ \\mathrm{h}$ post-tretinoin application using piecewise constant $k(t)$ appropriate to the presence or absence of BPO radicals and light. Select the regimen that maximizes $C(2)/C_0$ while maintaining acne control and explains the chemical incompatibility by temporal separation.\n\nA. Apply benzoyl peroxide at $\\text{22:00}$ and apply tretinoin at $\\text{22:30}$ (same night).\n\nB. Apply benzoyl peroxide at $\\text{08:00}$ (day) and apply tretinoin at $\\text{21:00}$ (night), with no other changes.\n\nC. Apply tretinoin at $\\text{07:00}$ (day) and apply benzoyl peroxide at $\\text{22:00}$ (night), with no other changes.\n\nD. Mix benzoyl peroxide and tretinoin and apply together at $\\text{07:00}$ (day).\n\nChoose the single best option.", "solution": "The fundamental principle governing the degradation of tretinoin is the first-order rate law, where the fraction of intact drug, $C(t)/C_0$, at time $t$ after application is given by:\n$$\n\\frac{C(t)}{C_0} = \\exp\\left(-\\int_0^t k(\\tau)\\,d\\tau\\right)\n$$\nWe are asked to calculate this fraction at $t=2\\ \\mathrm{h}$ post-tretinoin application for four different dosing regimens. The pseudo-first-order rate constant, $k(t)$, is piecewise constant and depends on the presence of daylight (light) and/or benzoyl peroxide (BPO)-derived radicals (ox). The parameter values are:\n-   Base rate in darkness: $k_{\\mathrm{dark}} = 0.02\\ \\mathrm{h}^{-1}$\n-   Base rate in daylight: $k_{\\mathrm{light}} = 0.10\\ \\mathrm{h}^{-1}$\n-   Additional rate due to BPO radicals: $k_{\\mathrm{ox}} = 0.20\\ \\mathrm{h}^{-1}$\n-   Duration of BPO radical generation: $T_{\\mathrm{rad}} = 3\\ \\mathrm{h}$\n\nFor a constant rate constant $k$ over an interval $\\Delta t$, the integral simplifies to $k \\cdot \\Delta t$. We wish to maximize the fraction of surviving tretinoin, $C(2)/C_0$, which is equivalent to minimizing the integrated rate, $\\int_0^2 k(\\tau)\\,d\\tau$.\n\n### Analysis of Each Dosing Regimen\n\n**A. Apply benzoyl peroxide at $\\text{22:00}$ and apply tretinoin at $\\text{22:30}$ (same night).**\n\nLet $t=0$ correspond to the time of tretinoin application at $\\text{22:30}$. We evaluate the degradation over the interval $t \\in [0, 2]\\ \\mathrm{h}$, which is from $\\text{22:30}$ to $\\text{00:30}$.\n-   **Lighting conditions:** The entire interval is at night (dark).\n-   **BPO radical presence:** BPO is applied at $\\text{22:00}$. Radicals are generated for $T_{\\mathrm{rad}} = 3\\ \\mathrm{h}$, lasting until $\\text{01:00}$. The entire analysis interval for tretinoin, from $\\text{22:30}$ to $\\text{00:30}$, falls within this period.\n-   **Rate constant:** The rate constant $k(t)$ is constant throughout the $2\\ \\mathrm{h}$ interval: $k(t) = k_{\\mathrm{dark}} + k_{\\mathrm{ox}} = 0.02\\ \\mathrm{h}^{-1} + 0.20\\ \\mathrm{h}^{-1} = 0.22\\ \\mathrm{h}^{-1}$.\n\nThe integrated rate is:\n$$\n\\int_0^2 k(\\tau)\\,d\\tau = (0.22\\ \\mathrm{h}^{-1}) \\times (2\\ \\mathrm{h}) = 0.44\n$$\nThe fraction of remaining tretinoin is:\n$$\n\\frac{C(2)}{C_0} = \\exp(-0.44) \\approx 0.6440\n$$\n**Verdict: Incorrect.** This regimen exposes tretinoin to significant oxidative degradation.\n\n**B. Apply benzoyl peroxide at $\\text{08:00}$ (day) and apply tretinoin at $\\text{21:00}$ (night), with no other changes.**\n\nLet $t=0$ correspond to the time of tretinoin application at $\\text{21:00}$. We evaluate over $t \\in [0, 2]\\ \\mathrm{h}$ (from $\\text{21:00}$ to $\\text{23:00}$).\n-   **Lighting conditions:** The entire interval is at night (dark).\n-   **BPO radical presence:** BPO is applied at $\\text{08:00}$. Radicals are generated until $\\text{08:00} + 3\\ \\mathrm{h} = \\text{11:00}$. By the time tretinoin is applied at $\\text{21:00}$, the BPO-derived radicals have long since dissipated.\n-   **Rate constant:** The rate constant $k(t)$ is constant throughout the $2\\ \\mathrm{h}$ interval: $k(t) = k_{\\mathrm{dark}} = 0.02\\ \\mathrm{h}^{-1}$.\n\nThe integrated rate is:\n$$\n\\int_0^2 k(\\tau)\\,d\\tau = (0.02\\ \\mathrm{h}^{-1}) \\times (2\\ \\mathrm{h}) = 0.04\n$$\nThe fraction of remaining tretinoin is:\n$$\n\\frac{C(2)}{C_0} = \\exp(-0.04) \\approx 0.9608\n$$\n**Verdict: Correct.** This regimen maximizes the survival of tretinoin by applying it in the dark and temporally separating it from the application of BPO, thus avoiding both photodegradation and oxidative degradation.\n\n**C. Apply tretinoin at $\\text{07:00}$ (day) and apply benzoyl peroxide at $\\text{22:00}$ (night), with no other changes.**\n\nLet $t=0$ correspond to the time of tretinoin application at $\\text{07:00}$. We evaluate over $t \\in [0, 2]\\ \\mathrm{h}$ (from $\\text{07:00}$ to $\\text{09:00}$).\n-   **Lighting conditions:** The entire interval is in daylight.\n-   **BPO radical presence:** BPO is applied at $\\text{22:00}$, long after the $2\\ \\mathrm{h}$ window of interest for tretinoin. No BPO radicals are present.\n-   **Rate constant:** The rate constant $k(t)$ is constant throughout the $2\\ \\mathrm{h}$ interval: $k(t) = k_{\\mathrm{light}} = 0.10\\ \\mathrm{h}^{-1}$.\n\nThe integrated rate is:\n$$\n\\int_0^2 k(\\tau)\\,d\\tau = (0.10\\ \\mathrm{h}^{-1}) \\times (2\\ \\mathrm{h}) = 0.20\n$$\nThe fraction of remaining tretinoin is:\n$$\n\\frac{C(2)}{C_0} = \\exp(-0.20) \\approx 0.8187\n$$\n**Verdict: Incorrect.** While oxidative degradation is avoided, significant photodegradation occurs due to daytime application, making it inferior to regimen B.\n\n**D. Mix benzoyl peroxide and tretinoin and apply together at $\\text{07:00}$ (day).**\n\nLet $t=0$ correspond to the time of application at $\\text{07:00}$. We evaluate over $t \\in [0, 2]\\ \\mathrm{h}$ (from $\\text{07:00}$ to $\\text{09:00}$).\n-   **Lighting conditions:** The entire interval is in daylight.\n-   **BPO radical presence:** BPO is applied simultaneously with tretinoin. Radicals are generated for $3\\ \\mathrm{h}$ (until $\\text{10:00}$), which covers the entire analysis interval.\n-   **Rate constant:** The rate constant $k(t)$ is constant throughout the $2\\ \\mathrm{h}$ interval: $k(t) = k_{\\mathrm{light}} + k_{\\mathrm{ox}} = 0.10\\ \\mathrm{h}^{-1} + 0.20\\ \\mathrm{h}^{-1} = 0.30\\ \\mathrm{h}^{-1}$.\n\nThe integrated rate is:\n$$\n\\int_0^2 k(\\tau)\\,d\\tau = (0.30\\ \\mathrm{h}^{-1}) \\times (2\\ \\mathrm{h}) = 0.60\n$$\nThe fraction of remaining tretinoin is:\n$$\n\\frac{C(2)}{C_0} = \\exp(-0.60) \\approx 0.5488\n$$\n**Verdict: Incorrect.** This regimen is the worst, as it subjects tretinoin to both photodegradation and oxidative degradation simultaneously, leading to the fastest rate of destruction.\n\n### Conclusion\n\nComparing the fractions of intact tretinoin after $2$ hours:\n-   Regimen A: $0.6440$\n-   Regimen B: $0.9608$\n-   Regimen C: $0.8187$\n-   Regimen D: $0.5488$\n\nThe regimen that maximizes the fraction of intact tretinoin, $C(2)/C_0$, is Regimen B. It achieves this by complete temporal separation of the two agents (BPO in the morning, tretinoin at night), which eliminates the oxidative degradation pathway ($k_{\\mathrm{ox}}$), and by applying tretinoin at night, which eliminates the photodegradation pathway ($k_{\\mathrm{light}}$ relative to $k_{\\mathrm{dark}}$). This leaves only the slow, baseline dark degradation, resulting in the highest drug survival. This regimen correctly addresses the chemical incompatibility by temporal separation.", "answer": "$$\\boxed{B}$$", "id": "4936264"}, {"introduction": "While designed for local action, topical drugs can be absorbed systemically, sometimes to a degree that poses a significant toxicological risk, especially when applied over large areas or under occlusion. This advanced problem challenges you to perform a comprehensive safety assessment for a high-strength salicylic acid preparation. You will construct a pharmacokinetic model from first principles—incorporating Fickian diffusion, the pH-partition hypothesis, and finite-dose constraints—to estimate the absorbed systemic dose and evaluate the risk of salicylate poisoning. [@problem_id:4936327]", "problem": "An adult patient is treated for extensive hyperkeratosis with a high-strength salicylic acid topical under full occlusion. The preparation is a hydroalcoholic gel containing salicylic acid at $20\\,\\%$ weight-by-weight, with density $1.0\\,\\mathrm{g/cm^3}$ and formulation $\\mathrm{pH}=3.0$. The product is applied uniformly at an areal dosage of $20\\,\\mathrm{mg/cm^2}$ over a body surface area of $6000\\,\\mathrm{cm^2}$ and kept under occlusion for $12\\,\\mathrm{h}$. Assume the patient’s body mass is $70\\,\\mathrm{kg}$.\n\nUse a first-principles percutaneous absorption framework grounded in diffusion and acid-base partitioning to estimate the absorbed systemic dose of salicylic acid and compare it to a systemic toxicity threshold. In your modeling, adhere to the following scientific bases and assumptions:\n\n- Apply Fick’s first law for steady-state transdermal flux under sink conditions across the stratum corneum. Treat the permeability coefficient for the unionized form of salicylic acid across hydrated stratum corneum under occlusion as a constant $P = 1.5 \\times 10^{-5}\\,\\mathrm{cm/s}$ (reflecting increased hydration and barrier disruption by occlusion). Do not assume any additional enhancement mechanisms beyond hydration.\n- Treat transport as limited to the unionized fraction of salicylic acid at the donor surface. Use the Henderson–Hasselbalch relationship for a weak acid with $\\mathrm{p}K_a = 2.97$ to compute the unionized fraction at the stated $\\mathrm{pH}$.\n- Consider a finite donor layer of thickness $h$ equal to the applied mass per area divided by the density of the formulation. Assume the donor concentration is spatially uniform and equal to the bulk formulation concentration, and ignore evaporation under occlusion. The maximum unionized mass available to cross the skin is constrained by the unionized content of this finite donor layer.\n- Under sink conditions, cumulative absorption predicted by diffusion cannot exceed the finite unionized donor supply; use the physically consistent minimum of these two predictions.\n\nLet the systemic toxicity threshold for salicylate be $150\\,\\mathrm{mg/kg}$. Compute the hazard quotient $\\mathrm{HQ}$ defined as the ratio of the estimated absorbed dose (in $\\mathrm{mg/kg}$) to the threshold $150\\,\\mathrm{mg/kg}$. Round your final $\\mathrm{HQ}$ to three significant figures and express it as a decimal number without units.", "solution": "The objective is to compute the Hazard Quotient ($\\mathrm{HQ}$), which requires determining the total systemic dose of salicylic acid absorbed by the patient. The problem specifies that the absorbed dose is the lesser of two quantities: the amount predicted by steady-state diffusion over the exposure time and the total amount of absorbable (unionized) drug available in the applied formulation.\n\n**1. Calculate the fraction of unionized salicylic acid**\n\nSalicylic acid is a weak acid. The fraction of the acid in its unionized, lipid-permeable form ($[HA]$) versus its ionized, poorly-permeable form ($[A^-]$) is governed by the formulation $\\mathrm{pH}$ and the acid's $\\mathrm{p}K_a$ via the Henderson-Hasselbalch relationship. The fraction of unionized acid, $f_u$, is given by:\n$$f_u = \\frac{[HA]}{[HA] + [A^-]} = \\frac{1}{1 + \\frac{[A^-]}{[HA]}}$$\nFrom the Henderson-Hasselbalch equation, $\\mathrm{pH} = \\mathrm{p}K_a + \\log_{10}\\left(\\frac{[A^-]}{[HA]}\\right)$, we have $\\frac{[A^-]}{[HA]} = 10^{\\mathrm{pH} - \\mathrm{p}K_a}$.\nSubstituting the given values $\\mathrm{pH} = 3.0$ and $\\mathrm{p}K_a = 2.97$:\n$$f_u = \\frac{1}{1 + 10^{(3.0 - 2.97)}} = \\frac{1}{1 + 10^{0.03}}$$\n\n**2. Calculate the donor-limited absorption amount ($M_{abs, donor}$)**\n\nThis is the maximum possible amount of salicylic acid that can be absorbed, as it is limited by the total quantity of unionized drug applied to the skin.\n\nFirst, we calculate the total mass of the formulation applied to the skin, $M_{form}$:\n$$M_{form} = D_{areal} \\times A = (20\\,\\mathrm{mg/cm^2}) \\times (6000\\,\\mathrm{cm^2}) = 120000\\,\\mathrm{mg} = 120\\,\\mathrm{g}$$\nNext, we find the total mass of salicylic acid ($SA$) within this formulation, $M_{SA,total}$:\n$$M_{SA,total} = M_{form} \\times C_{SA, w/w} = 120\\,\\mathrm{g} \\times 0.20 = 24\\,\\mathrm{g} = 24000\\,\\mathrm{mg}$$\nThe total mass of *unionized* salicylic acid available for absorption is the product of the total mass of SA and the unionized fraction $f_u$:\n$$M_{abs, donor} = M_{SA,total} \\times f_u = 24000\\,\\mathrm{mg} \\times \\frac{1}{1 + 10^{0.03}}$$\n\n**3. Calculate the flux-limited absorption amount ($M_{abs, flux}$)**\n\nThis is the amount of drug that would cross the skin if the supply were infinite and the concentration remained constant, based on Fick's first law. The steady-state flux, $J$, is given by:\n$$J = P \\times C_u$$\nwhere $P$ is the permeability coefficient and $C_u$ is the concentration of the unionized drug in the vehicle.\nThe total concentration of SA in the formulation, $C_{total}$, is:\n$$C_{total} = C_{SA, w/w} \\times \\rho_{form} = 0.20 \\times 1.0\\,\\mathrm{g/cm^3} = 0.2\\,\\mathrm{g/cm^3} = 200\\,\\mathrm{mg/cm^3}$$\nThe concentration of the unionized species is:\n$$C_u = C_{total} \\times f_u = (200\\,\\mathrm{mg/cm^3}) \\times \\frac{1}{1 + 10^{0.03}}$$\nNow, we calculate the flux $J$:\n$$J = (1.5 \\times 10^{-5}\\,\\mathrm{cm/s}) \\times C_u = (1.5 \\times 10^{-5}\\,\\mathrm{cm/s}) \\times (200\\,\\mathrm{mg/cm^3}) \\times \\frac{1}{1 + 10^{0.03}}$$\nThe total mass absorbed over time $T$ and area $A$ is $M_{abs, flux} = J \\times A \\times T$. We must convert the time $T = 12\\,\\mathrm{h}$ to seconds:\n$$T = 12\\,\\mathrm{h} \\times 3600\\,\\mathrm{s/h} = 43200\\,\\mathrm{s}$$\n$$M_{abs, flux} = \\left( (1.5 \\times 10^{-5}\\,\\mathrm{cm/s}) \\times (200\\,\\mathrm{mg/cm^3}) \\times f_u \\right) \\times (6000\\,\\mathrm{cm^2}) \\times (43200\\,\\mathrms) $$\n\n**4. Determine the actual absorbed mass ($M_{abs}$)**\n\nThe problem states that the actual absorbed mass is the physically consistent minimum of the two predictions:\n$$M_{abs} = \\min(M_{abs, donor}, M_{abs, flux})$$\nLet's evaluate the terms. $f_u = \\frac{1}{1 + 10^{0.03}} \\approx \\frac{1}{1+1.0715} \\approx 0.48274$.\n$$M_{abs, donor} \\approx 24000\\,\\mathrm{mg} \\times 0.48274 \\approx 11586\\,\\mathrm{mg}$$\n$$M_{abs, flux} \\approx (1.5 \\times 10^{-5}\\,\\mathrm{cm/s}) \\times (200\\,\\mathrm{mg/cm^3}) \\times 0.48274 \\times (6000\\,\\mathrm{cm^2}) \\times (43200\\,\\mathrms) \\approx 375373\\,\\mathrm{mg}$$\nSince $11586\\,\\mathrm{mg} < 375373\\,\\mathrm{mg}$, the absorption is limited by the finite amount of unionized drug available in the applied layer.\n$$M_{abs} = M_{abs, donor} = 24000 \\times \\frac{1}{1 + 10^{0.03}}\\,\\mathrm{mg}$$\n\n**5. Calculate the systemic dose and Hazard Quotient (HQ)**\n\nThe systemic dose, $D_{sys}$, is the absorbed mass per unit of patient body mass:\n$$D_{sys} = \\frac{M_{abs}}{M_{patient}} = \\frac{24000}{70} \\times \\frac{1}{1 + 10^{0.03}}\\,\\mathrm{mg/kg}$$\nThe Hazard Quotient ($\\mathrm{HQ}$) is the ratio of this systemic dose to the toxicity threshold:\n$$\\mathrm{HQ} = \\frac{D_{sys}}{Threshold_{tox}} = \\frac{M_{abs}}{M_{patient} \\times Threshold_{tox}}$$\n$$\\mathrm{HQ} = \\frac{24000\\,\\mathrm{mg}}{ (70\\,\\mathrm{kg}) \\times (150\\,\\mathrm{mg/kg}) } \\times \\frac{1}{1 + 10^{0.03}} = \\frac{24000}{10500} \\times \\frac{1}{1 + 10^{0.03}}$$\n$$\\mathrm{HQ} = \\frac{240}{105} \\times \\frac{1}{1 + 10^{0.03}} = \\frac{8}{3.5} \\times \\frac{1}{1 + 10^{0.03}} \\approx 2.2857 \\times 0.48274 \\approx 1.1034$$\nRounding to three significant figures, the Hazard Quotient is $1.10$.", "answer": "$$\\boxed{1.10}$$", "id": "4936327"}]}